We have designed our technology to overcome current technical shortcomings and help healthcare systems move towards a more cost-effective and sustainable path for screening of genetic disorders.
gMendel® is the only AI cloud-based end-to-end IVD certified technology for accurate, real time & affordable screening of multiple rare diseases & beyond. Moreover, gMendel®’s technology is automated, transcending the need for bioinformatician‘s intervention, reducing the experimental errors & costs. This improves accessibility and has a potential to revolutionize genetic analysis without any change to current health care protocols.
Currently, the diagnosis of genetic disorders relies on a set of non-accurate conventional techniques such as karyotyping/FISH, chromosomal microarrays (CMA), Sanger sequencing, comparative genome hybridization (CGH) arrays, MLPA- & PCR-based techniques and tandem mass spectrometry.
In addition, advanced technologies such as next generation sequencing and optical genome mapping (OGM) are still characterized by high complexity, high cost and high risk for patients, particularly in the case of Laboratory Developed Tests (LDTs), which are designed, manufactured and used within a single laboratory.
As a result, even after dozens of medical examinations, which take many years, significant number of patients are still misdiagnosed, creating a heavy human, economic and societal burden. There is an apparent unmet clinical need for better, faster and affordable screening/diagnosis of wide range of genetic disorders.
gMendel® technology is a groundbreaking, AI-powered solution that delivers accurate, fast, and affordable screening for genetic conditions at scale. By facilitating earlier interventions, it reduces patient suffering and has the potential to save healthcare systems billions globally. What sets gMendel® apart is its scalability and focus on mass genetic screening rather than individual diagnostics. Operating on a SaaS model, our platform processes hundreds of thousands of samples, significantly enhancing the speed and efficiency of genetic screening for large populations.
This approach not only expedites diagnosis but also democratizes access to genetic insights, enabling large-scale health interventions that are both feasible and financially sustainable. By seamlessly integrating genomics with AI, gMendel® surpasses existing technologies, delivering faster, more affordable, and superior results—all without requiring skilled personnel (i.e. Bioinformaticians for analysis and Geneticists for interpretation). In 2022, we became the world’s first IVD-certified technology for screening genetic disorders using long-read sequencing and AI, proudly achieving the CE mark.